The Executive Committee on Personalized Health and Related Technologies (PHRT) has supported the PROGNOSTIC translational Project with a Grant of CHF 2 million
The translational project "PROGNOSTICS", proposed by a consortium led by Prof. Roger Schibli, received CHF 2 million funding from the PHRT initiative of the ETH Domain(https://www.sfa-phrt.ch/two-clinical-trial-projects-launched-transforming-clinical-care-with-eth-technologies/). The study is being conducted with the Co-applicants Prof. Dr. med. Damian Wild at the University Hospital Basel and Prof. Dr. Nicola Aceto of the ETHZ. The consortium will test a new radiopharmaceutical developed at the Center for Radiopharmaceutical Sciences in 36 patients with advanced prostate cancer.
Professor Dr. Cristina Müller.
Prof. Roger Schibli was awarded an Honorary Fellow of the Society of Radiopharmaceutical Sciences (SRS)
Prof. Roger Schibli was awarded an Honorary Fellow of the Society of Radiopharmaceutical Sciences (SRS) “in recognition of substantial contribution to the SRS”.
Prof. Roger Schibli (third person from the left).
Dr. Francesca Borgna, former Marie Curie Fellow at the Center for Radiopharmaceutical Sciences awarded by the Institute of Pharmaceutical Sciences in 2022 and gave the IPW Young Scientist lecture entitled: "Combination of Terbium-161 with Somatostatin Receptor Antagonists: a Potential Paradigm Shift for the Treatment of Neuroendocrine Neoplasm.